Mar, 16, 2023
Regel Therapeutics announces its participation at the Dravet Syndrome Conference and attendance at the European Dravet Syndrome Advanced Therapies Meeting in Madrid, Spain on March 23rd and 24th 2023.
CAMBRIDGE, Mass., and BERKELEY, Calif March 16th 2023 / PRNewswire -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, today announced that Jordane Dimidschstein, Ph.D., co-founder and COO, will present Regel’s technology and pipeline at the Dravet Conference...
Jan, 27, 2023
Regel Therapeutics launches its website and welcomes Andrew Schiermeier to its Board of Directors.
Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board. The company launches its website with key pipeline information Regel adds industry leader Andrew Schiermeier, Ph.D to its Board of Directors Regel announces its Scientific...